Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VR-205 in Primary IgA Nephropathy Patients at Risk of ESRD
jRCT2031240044Active, not recruiting
- Sponsor
- Viatris
- Start
- Jun 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial in IgA nephropathy (IgAN), sponsored by Viatris. Primary endpoint: Geometric mean change in UPCR at 9 months. Started Jun 2024; status: active, not recruiting.
02
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2031240044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240044.